GANXGain Therapeutics, Inc.

Nasdaq gaintherapeutics.com


$ 1.14 $ 0.02 (1.79 %)    

Tuesday, 02-Jul-2024 10:52:54 EDT
QQQ $ 485.80 $ 5.91 (1.23 %)
DIA $ 392.08 $ 1.24 (0.32 %)
SPY $ 547.35 $ 3.61 (0.66 %)
TLT $ 90.28 $ -0.39 (-0.43 %)
GLD $ 214.93 $ -0.64 (-0.3 %)
$ 1.12
$ 1.13
$ 1.16 x 100
$ 0.00 x 0
$ 1.13 - $ 1.14
$ 1.11 - $ 5.33
625,155
na
20.14M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-gain-therapeutics-lowers-price-target-to-8

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price...

 reported-earlier-gain-therapeutics-prices-11m-public-offering-of-7116547-common-shares-at-135share-and-pre-funded

Gain Therapeutics announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a pub...

 gain-therapeutics-plans-to-offer-and-sell-shares-of-its-common-stock-or-pre-funded-warrants-in-lieu-thereof-in-public-offering

Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre...

 hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

 hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

 hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

 hc-wainwright--co-reiterates-buy-on-gain-therapeutics-maintains-9-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...

 gain-therapeutics-reports-results-from-single-ascending-dose-part-of-phase-1-clinical-trial-of-gt-02287-novel-gcase-targeting-small-molecule-therapy-for-gba1-parkinsons-disease

GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse eve...